P A Ory

5.0k total citations · 3 hit papers
21 papers, 3.9k citations indexed

About

P A Ory is a scholar working on Rheumatology, Immunology and Molecular Biology. According to data from OpenAlex, P A Ory has authored 21 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Rheumatology, 7 papers in Immunology and 6 papers in Molecular Biology. Recurrent topics in P A Ory's work include Rheumatoid Arthritis Research and Therapies (14 papers), Spondyloarthritis Studies and Treatments (10 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). P A Ory is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (14 papers), Spondyloarthritis Studies and Treatments (10 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). P A Ory collaborates with scholars based in United States, Canada and Belgium. P A Ory's co-authors include John T. Sharp, Philip J. Mease, Wayne Tsuji, Christopher T. Ritchlin, Stanley Cohen, Dafna D. Gladman, Renee Perdok, Ernest Choy, Ira M. Goldstein and Sarah Clarkson and has published in prestigious journals such as Journal of Clinical Investigation, The Journal of Experimental Medicine and The Journal of Immunology.

In The Last Decade

P A Ory

21 papers receiving 3.8k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double‐blind, randomized, placebo‐controlled trial

2005 702 citations Philip J. Mease, Dafna D. Gladman et al. Arthritis & Rheumatism profile →
Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression

2004 697 citations Philip J. Mease, Alan Kivitz et al. Arthritis & Rheumatism profile →
Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept

2008 408 citations D. van der Heijde, Robert Landewé et al. Arthritis & Rheumatism profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
P A Ory	2.8k	2.1k	1.4k	643	391	21	3.9k
Arthur F. Kavanaugh	2.8k 1.0×	1.0k 0.5×	1.2k 0.9×	266 0.4×	539 1.4×	27	3.7k
Elizabeth C. Hsia	3.1k 1.1×	1.7k 0.8×	1.6k 1.2×	135 0.2×	234 0.6×	109	3.9k
Elli Kruithof	2.1k 0.8×	1.1k 0.5×	874 0.6×	312 0.5×	147 0.4×	41	2.6k
Edward M Vital	2.6k 0.9×	2.0k 0.9×	333 0.2×	271 0.4×	995 2.5×	147	3.9k
J. D. Reveille	2.1k 0.7×	1.3k 0.6×	401 0.3×	286 0.4×	291 0.7×	32	2.6k
Irene van der Horst‐Bruinsma	2.2k 0.8×	946 0.5×	465 0.3×	253 0.4×	585 1.5×	72	2.7k
Serena Bugatti	1.3k 0.5×	655 0.3×	301 0.2×	258 0.4×	349 0.9×	89	2.1k
Hildrun Haibel	6.3k 2.3×	3.5k 1.7×	1.9k 1.4×	535 0.8×	50 0.1×	128	6.8k
William Shergy	1.2k 0.4×	561 0.3×	481 0.3×	228 0.4×	274 0.7×	24	1.9k
Rosario García‐Vicuña	942 0.3×	689 0.3×	384 0.3×	358 0.6×	225 0.6×	120	2.1k

Countries citing papers authored by P A Ory

Since Specialization

Citations

This map shows the geographic impact of P A Ory's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P A Ory with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P A Ory more than expected).

Fields of papers citing papers by P A Ory

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P A Ory. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P A Ory. The network helps show where P A Ory may publish in the future.

Co-authorship network of co-authors of P A Ory

This figure shows the co-authorship network connecting the top 25 collaborators of P A Ory. A scholar is included among the top collaborators of P A Ory based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P A Ory. P A Ory is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sharp, John T., et al.. (2010). Denosumab prevents metacarpal shaft cortical bone loss in patients with erosive rheumatoid arthritis. Arthritis Care & Research. 62(4). 537–544. 49 indexed citations

Deodhar, Atul, Robin K. Dore, David R. Mandel, et al.. (2010). Denosumab‐mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients. Arthritis Care & Research. 62(4). 569–574. 96 indexed citations

Anandarajah, Allen, P A Ory, David Salonen, et al.. (2009). Effect of adalimumab on joint disease: features of patients with psoriatic arthritis detected by magnetic resonance imaging. Annals of the Rheumatic Diseases. 69(1). 206–209. 42 indexed citations

Cohen, Stanley, Robin K. Dore, Nancy E. Lane, et al.. (2008). Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve‐month, multicenter, randomized, double‐blind, placebo‐controlled, phase II clinical trial. Arthritis & Rheumatism. 58(5). 1299–1309. 435 indexed citations

Heijde, D. van der, Robert Landewé, Steven Einstein, et al.. (2008). Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis & Rheumatism. 58(5). 1324–1331. 408 indexed citations breakdown →

Mease, Philip J., P A Ory, John T. Sharp, et al.. (2008). Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Annals of the Rheumatic Diseases. 68(5). 702–709. 214 indexed citations

Gladman, Dafna D., Philip J. Mease, Christopher T. Ritchlin, et al.. (2007). Adalimumab for long‐term treatment of psoriatic arthritis: Forty‐eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis & Rheumatism. 56(2). 476–488. 238 indexed citations

Mease, Philip J., Alan Kivitz, Francis X. Burch, et al.. (2006). Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept.. PubMed. 33(4). 712–21. 167 indexed citations

Mease, Philip J., John T. Sharp, P A Ory, et al.. (2005). Adalimumab treatment effects on radiographic progression of joint disease in patients with psoriatic arthritis: Results from ADEPT. Annals of the Rheumatic Diseases. 64. 320–320. 16 indexed citations

10.

Mease, Philip J., Dafna D. Gladman, Christopher T. Ritchlin, et al.. (2005). Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double‐blind, randomized, placebo‐controlled trial. Arthritis & Rheumatism. 52(10). 3279–3289. 702 indexed citations breakdown →

11.

Ory, P A, D. Gladman, & Philip J. Mease. (2005). Psoriatic arthritis and imaging. Annals of the Rheumatic Diseases. 64. ii55–ii57. 97 indexed citations

12.

Mease, Philip J., Alan Kivitz, Francis X. Burch, et al.. (2004). Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression. Arthritis & Rheumatism. 50(7). 2264–2272. 697 indexed citations breakdown →

13.

Ory, P A. (2003). Radiography in the assessment of musculoskeletal conditions. Best Practice & Research Clinical Rheumatology. 17(3). 495–512. 25 indexed citations

14.

Ory, P A. (2003). Interpreting radiographic data in rheumatoid arthritis. Annals of the Rheumatic Diseases. 62(7). 597–604. 61 indexed citations

15.

Bridges, Alan J., Daniel G. Malone, Marcus Y. Chen, et al.. (1991). Human Synovial Mast Cell Involvement in Rheumatoid Arthritis and Osteoarthritis. Relationship to Disease Type, Clinical Activity, and Antirheumatic Therapy. Arthritis & Rheumatism. 34(9). 1116–1124. 57 indexed citations

16.

Clark, Marcus R., Susan G. Stuart, Robert P. Kimberly, P A Ory, & Ira M. Goldstein. (1991). A single amino acid distinguishes the high‐responder from the low‐responder form of Fc receptor II on human monocytes. European Journal of Immunology. 21(8). 1911–1916. 78 indexed citations

17.

Ory, P A, et al.. (1989). Characterization of polymorphic forms of Fc receptor III on human neutrophils.. Journal of Clinical Investigation. 83(5). 1676–1681. 89 indexed citations

18.

Ory, P A, et al.. (1989). Sequences of complementary DNAs that encode the NA1 and NA2 forms of Fc receptor III on human neutrophils.. Journal of Clinical Investigation. 84(5). 1688–1691. 151 indexed citations

19.

Clark, Marcus R., Sarah Clarkson, P A Ory, Neil Stollman, & Ira M. Goldstein. (1989). Molecular basis for a polymorphism involving Fc receptor II on human monocytes.. The Journal of Immunology. 143(5). 1731–1734. 96 indexed citations

20.

Clarkson, Sarah & P A Ory. (1988). CD16. Developmentally regulated IgG Fc receptors on cultured human monocytes.. The Journal of Experimental Medicine. 167(2). 408–420. 151 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact